Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis | MicrobiomeTrials← Back to trialsNCT07727967
Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis
CompletedNAINTERVENTIONAL
Trial Details
Start: 2022-07-01Est. Completion: 2023-12-15
Enrollment target: 100 participants Locations- The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
Other microbiome trials you might be interested in
Bacterial VaginosisCandidal Vaginitis
This is a randomized, double-blind, placebo-controlled, two-arm parallel-group clinical study evaluating the efficacy an…
Naples, ItalyEst. completion Nov 30, 2026
Genitourinary Syndrome of Menopause (GSM)Bacterial VaginosisVulvovaginal Candidiasis (VVC)
Vaginal disorders, including vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), and genitourinary syndrome of men…
Salvador, BrazilEst. completion Jun 30, 2027